secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2022-12-13T23:59:59+00:00
Accession:  0001396814-22-000072
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira reports Nov 2022 preliminary net product sales of $57.5M; EXPAREL unit volumes up 4% YoY
--------------------------------------------------------------------------------

- EXPAREL net sales $46.0M (99% of Nov 2021); unit volumes 104% of Nov 2021; selling days flat at 20.
- ZILRETTA net sales $10.0M; iovera° net sales $1.5M (unchanged YoY).
- Expanded contracting and 340B pricing expected to drive volume growth and be accretive in 2023.
- No 2022 revenue or gross margin guidance provided due to COVID-19 and labor shortage uncertainty.
- Company continues monthly intra-quarter sales reporting until visibility improves.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681422000072/0001396814-22-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681422000072/pcrx-20221213.htm
  HTML page:      https://secwatch.observer/filing/0001396814-22-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer